LOGIN  |  REGISTER
Cue Biopharma
C4 Therapeutics

Community Health Systems Completes Divestiture of Cleveland, Tennessee, Hospital to Hamilton Health Care System

August 01, 2024 | Last Trade: US$2.76 0.04 -1.43

FRANKLIN, Tenn. / Aug 01, 2024 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) announced today that certain subsidiaries of the Company have completed the sale of 351-bed Tennova Healthcare – Cleveland in Cleveland, Tennessee, and certain related businesses to Hamilton Health Care System, Inc. for $160 million. Additional cash consideration may be received contingent upon potential changes to certain supplemental reimbursement programs. The transaction is effective August 1, 2024.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 39 distinct markets across 15 states. The Company’s subsidiaries own or lease 70 affiliated hospitals with more than 11,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers.

The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page